Lexeo Therapeutics (NASDAQ:LXEO) Insider Sells 22,306 Shares

Posted by Francis Steltz on Jul 1st, 2026

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) insider Narinder Pal Bhalla sold 22,306 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the transaction, the insider owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO traded down $0.21 during mid-day trading on Wednesday, hitting $4.45. The company had a trading volume of 852,557 shares, compared to its average volume of 948,339. The company has a market capitalization of $349.41 million, a PE ratio of -3.07 and a beta of 1.38. Lexeo Therapeutics, Inc. has a 1-year low of $3.60 and a 1-year high of $10.99. The business’s 50-day simple moving average is $5.16 and its 200 day simple moving average is $6.67.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. On average, analysts expect that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Trading of Lexeo Therapeutics

Large investors have recently bought and sold shares of the business. Allworth Financial LP lifted its stake in shares of Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after purchasing an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after buying an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Lexeo Therapeutics in the fourth quarter valued at about $37,000. California State Teachers Retirement System increased its holdings in Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in shares of Lexeo Therapeutics during the 2nd quarter valued at approximately $50,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Analysts Set New Price Targets

LXEO has been the topic of a number of recent analyst reports. Chardan Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Weiss Ratings downgraded shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, JPMorgan Chase & Co. lowered their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.75.

View Our Latest Report on Lexeo Therapeutics

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.